Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

By R. Morgan, M. Dudley, J. Wunderlich, M. Hughes, Jie Yang, R. Sherry, R. Royal, S. Topalian, U. Kammula, N. Restifo and 6 more. Science, 2006

2,728 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a03f81398213d7e04ce2a51ea7aff591cddaff3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Immunology

In Oncology

Citations in the corpus

Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “The effectiveness of adoptive tumor immunotherapy has been significantly strengthened by the application of re-directed tumorreactive T cells [136].”
Adoptive immunotherapy for cancer: harnessing the T cell response (2012, background): “T cells can be genetically engineered, using a variety of techniques, to express TCRs with a high affinity and excellent specificity for target antigen”
Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013, neutral): “ESO-1 TCR, ALVAC, IL-2 41 1 PR (5) None”
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011, background): “circulating lymphocytes and the use of these genetically engineered autologous cells for adoptive transfer are being explored in ongoing clinical trials (41, 42).”
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011, background): “There are promising Phase I/II data with ACT using T cells, including clinical responses with genetically engineered T cell”
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011, background): “In the first trial, to our knowledge, to examine the in vivo efficacy of TCR-transduced T cells in patients with cancer, tumor regression was observed in two of 13 patients receiving autologous T cells that were transduced with a MART-1–reactive TCR.(4) In subsequent trials carried out with highavid”
Melanoma biology and new targeted therapy (2007, background): “However, recent trials of genetically engineered lymphocyte transfer have shown promise, with 2 (out of 17) patients achieving full remission for 18 month”
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells (2011, background): “We have previously shown that drugs affecting ARG and NOS activity reduce intratumoral protein nitration and restore TIL function, suggesting efforts, is to modify the lymphocyte TCR via retroviral or lentiviral transduction of transgenic receptors, thus enabling cells to recognize the tumor-related”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “One low-affinity TCR that was HLA-A2 restricted was found to be well tolerated but had low antitumor effects (Morgan et al., 2006).”
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation (2021, background): “, by the observations that the presence of activated CD8T cells in cancers are associated with improved survival (20) and adoptive immunotherapy with T cells engineered to express TCRs from tumor-reactive CD8T cells can lead to cancer regression (21)].”
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (2009, background): “T cell proliferative and survival capacities have been correlated with tumor responses in mice and humans receiving adoptive T cell–based therapie”